140 related articles for article (PubMed ID: 27235914)
1. Inverted Pyramid of Care.
Sonek JD; Kagan KO; Nicolaides KH
Clin Lab Med; 2016 Jun; 36(2):305-17. PubMed ID: 27235914
[TBL] [Abstract][Full Text] [Related]
2. [Clinical application of noninvasive prenatal diagnosis using cell free fetal DNA in maternal plasma].
Hou QF; Wu D; Chu Y; Kang B; Liao SX; Yang YL; Zhang CY; Zhang JX; Wu G
Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):813-7. PubMed ID: 23302120
[TBL] [Abstract][Full Text] [Related]
3. Screening at 11-13+6 weeks' gestation.
Sonek JD; Nicolaides KH; Janku P
Ceska Gynekol; 2012 Apr; 77(2):92-104. PubMed ID: 22702065
[TBL] [Abstract][Full Text] [Related]
4. Turning the pyramid of prenatal care.
Nicolaides KH
Fetal Diagn Ther; 2011; 29(3):183-96. PubMed ID: 21389681
[TBL] [Abstract][Full Text] [Related]
5. A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH
Prenat Diagn; 2011 Jan; 31(1):3-6. PubMed ID: 21210474
[No Abstract] [Full Text] [Related]
6. Optimizing use of existing prenatal genetic tests: Screening and diagnostic testing for aneuploidy.
Stoll K; Norton ME
Semin Perinatol; 2018 Aug; 42(5):296-302. PubMed ID: 30209012
[TBL] [Abstract][Full Text] [Related]
7. Effects of knowledge, education, and experience on acceptance of first trimester screening for chromosomal anomalies.
Stefansdottir V; Skirton H; Jonasson K; Hardardottir H; Jonsson JJ
Acta Obstet Gynecol Scand; 2010 Jul; 89(7):931-8. PubMed ID: 20235896
[TBL] [Abstract][Full Text] [Related]
8. Ten years of experience with first-trimester screening for fetal aneuploidy employing biochemistry from gestational weeks 6+0 to 13+6.
Tørring N; Petersen OB; Uldbjerg N
Fetal Diagn Ther; 2015; 37(1):51-7. PubMed ID: 25138113
[TBL] [Abstract][Full Text] [Related]
9. Modifying Risk of Aneuploidy with a Positive Cell-Free Fetal DNA Result.
Long AA; Abuhamad AZ; Warsof SL
Clin Lab Med; 2016 Jun; 36(2):249-59. PubMed ID: 27235910
[TBL] [Abstract][Full Text] [Related]
10. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience.
Spencer K; Spencer CE; Power M; Dawson C; Nicolaides KH
BJOG; 2003 Mar; 110(3):281-6. PubMed ID: 12628268
[TBL] [Abstract][Full Text] [Related]
11. Ethical dimensions of first-trimester fetal aneuploidy screening.
Chervenak FA; McCullough LB
Clin Obstet Gynecol; 2014 Mar; 57(1):226-31. PubMed ID: 24351442
[TBL] [Abstract][Full Text] [Related]
12. First-trimester prenatal diagnosis performed on pregnant women with fetal ultrasound abnormalities: the reliability of interphase fluorescence in situ hybridization (FISH) on mesenchymal core for the main aneuploidies.
Toutain J; Epiney M; Begorre M; Dessuant H; Vandenbossche F; Horovitz J; Saura R
Eur J Obstet Gynecol Reprod Biol; 2010 Apr; 149(2):143-6. PubMed ID: 20045588
[TBL] [Abstract][Full Text] [Related]
13. Early fetal anatomy screening: who, what, when and why?
Van Mieghem T; Hindryckx A; Van Calsteren K
Curr Opin Obstet Gynecol; 2015 Apr; 27(2):143-50. PubMed ID: 25689240
[TBL] [Abstract][Full Text] [Related]
14. First trimester contingent testing with either nuchal translucency or cell-free DNA. Cost efficiency and the role of ultrasound dating.
Conner P; Gustafsson S; Kublickas M
Acta Obstet Gynecol Scand; 2015 Apr; 94(4):368-75. PubMed ID: 25581307
[TBL] [Abstract][Full Text] [Related]
15. [Non-invasive prenatal test in the diagnosis of aneuploidy 13, 18 and 21--theoretical and practical aspects].
Stembalska A; Łaczmańska I; Lech D
Ginekol Pol; 2011 Feb; 82(2):126-32. PubMed ID: 21574485
[TBL] [Abstract][Full Text] [Related]
16. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
17. The evolution of prenatal testing: how NIPT is changing the landscape in fetal aneuploidy screening.
Wolfberg A
MLO Med Lab Obs; 2016 Jan; 48(1):18. PubMed ID: 26887093
[No Abstract] [Full Text] [Related]
18. Non-invasive aneuploidy detection using free fetal DNA and RNA in maternal plasma: recent progress and future possibilities.
Go AT; van Vugt JM; Oudejans CB
Hum Reprod Update; 2011; 17(3):372-82. PubMed ID: 21076134
[TBL] [Abstract][Full Text] [Related]
19. Cell-free DNA screening for fetal aneuploidy as a clinical service.
Cuckle H; Benn P; Pergament E
Clin Biochem; 2015 Oct; 48(15):932-41. PubMed ID: 25732593
[TBL] [Abstract][Full Text] [Related]
20. A prospective analysis of cell-free fetal DNA concentration in maternal plasma as an indicator for adverse pregnancy outcome.
Bauer M; Hutterer G; Eder M; Majer S; Leshane E; Johnson KL; Peter I; Bianchi DW; Pertl B
Prenat Diagn; 2006 Sep; 26(9):831-6. PubMed ID: 16832830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
